Adjunctive treatment with Aripiprazole for Risperidone –induced hyperprolactinemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307182181N6

Enrollment

Registered

2013-07-28

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperprolactinemia induced by risperidone. Hyperprolactinaemia

Interventions

aripiprazole is added on risperidone if : 1. serum prolactine > 200 mg/dl or 2.appearing any symptoms or signs of hyperprolactinemia.

Treatment - Drugs

aripiprazole is added on risperidone if : 1. serum prolactine > 200 mg/dl or 2.appearing any symptoms or signs of hyperprolactinemia

Eligibility

Sex/Gender

Female

Age

20 Years to 49 Years

Inclusion criteria

Inclusion criteria: inclusion criterias : 1.hyperprolactinemia 2. women in reproductive age 3.candidate for risperidone continuation exclusion criterias: 1.previous amenorrhea 2.breastfeeding 3.pregnancy 4.renal failure 5. hypothyroidism 6. pituitary tumors 7. consumption of methyldopa, levodopa,cimethidine, strogen, opium derivatives

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum prolactin level. Timepoint: weekly for first 2 weeks then monthly for 3 months. Method of measurement: mg/dl.	—

Secondary

Measure	Time frame
Drug side effect. Timepoint: the end of study. Method of measurement: patient interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Ranjbar Kouchaksaraei

razi hospital

fk_ranjbar@yahoo.comranjbarf@tbzmed.ac.ir+98 41 1380 3353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026